UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
Amendment No. 1
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2009
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ________to _________
Commission file number 0-21419
Cardo Medical, Inc.
(Exact name of Registrant as Specified in its Charter)
|
|
|
|
|
|
9701 Wilshire Blvd., Suite 1100
Beverly Hills, CA 90212
(Address of Principal Executive Offices including Zip Code)
(310) 274-2036
(Registrant's Telephone Number, Including Area Code)
8899 Beverly Boulevard, Suite 619, Los Angeles, CA 90048
(Former name, former address and former fiscal year, if changed since last report) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days.
YES x NO ¨ Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES ¨ NO ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):
|
Large accelerated filer ¨ |
Accelerated filer ¨ |
Non-accelerated filer ¨
|
Smaller reporting company x |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
APPLICABLE ONLY TO CORPORATE ISSUERS
State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date:
As of March 31, 2009, 203,360,271 shares of the issuer's common stock, par value of $0.001 per share, were outstanding.
EXPLANATORY NOTE Cardo Medical, Inc. is filing this Amendment No. 1 to its Quarterly Report on Form 10-Q for the period ended March 31,
2009, filed with the Securities and Exchange Commission (the "SEC") on May 15, 2009 (the "Original Filing"), solely for the purpose of
amending the disclosure in Item 4T - Controls and Procedures. This Form 10-Q/A continues to speak as of the date of the Original Filing,
March 31, 2009. ITEM 4T - CONTROLS AND PROCEDURES Disclosure controls and procedures are controls and other procedures that are designed to ensure that information
required to be disclosed in company reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized
and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and
procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in company
reports filed or submitted under the Securities Exchange Act of 1934 is accumulated and communicated to management, including our chief
executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure. As required by Rules 13a-15
and 15d-15 under the Securities Exchange Act of 1934, our chief executive officer and chief financial officer carried out an evaluation of the
effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2009. Based upon their evaluation, and
as a result of previously identified material weakness in internal control over financial reporting as discussed in our Annual Report on Form 10-
K for the year ended December 31, 2008, they concluded that our disclosure controls and procedures were not effective as of March 31, 2009.
Our management has discussed the material weakness in our internal control over financial reporting with our audit committee. In an effort to
remediate the identified material weaknesses, we have documented our process and procedures governing our internal reporting. We also
plan to implement further changes to our internal control over financial reporting, including (1) a re-evaluation of our staffing needs, and (2)
analysis of unusual transactions as they are occurring to allow adequate time for multiple levels of review. There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f)
under the Exchange Act) during the quarter ended March 31, 2009 that have materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting. 1
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.
YES ¨
NO x
|
|
CARDO MEDICAL, INC. |
|
|
|
|
|
|
|
|
|
|
Date: August 4, 2009 |
By: |
/s/ Andrew Brooks |
|
|
|
Andrew Brooks |
|
|
|
Chief Executive Officer |
|
|
|
|
|
|
|
|
|
Date: August 4, 2009 |
By: |
/s/ Derrick Romine |
|
|
|
Derrick Romine |
|
|
|
Chief Financial Officer |
3
INDEX TO EXHIBITS
3